AstraZeneca pledges more Evusheld doses to US, bringing its antibody supply deal to $855M

A little more than a month after AstraZeneca sold the U.S. half a million doses of its COVID-19 antibody combo, the British drugmaker and U.S. officials are expanding their supply deal once more. AZ and the U.S. Department of Health and Human Services have locked up an agreement for a total of 1 million additional doses of AstraZeneca’s long-acting antibody cocktail Evusheld, also known as tixagevimab plus cilgavimab, the company said Monday. The deal includes the 500,000 doses the U.S. purchased in January plus an initial order for 700,000 Evusheld doses, which are already being administered around the country, AZ said. The latest tranche, unveiled Monday, covers the purchase of 500,00 doses by the U.S. government. The total value of the agreement for the manufacture, distribution and storage of Evusheld is $855 million, an AstraZeneca spokesperson said over email. The U.S. has now locked up a total of 1.7 million doses from AZ.